Radical Cystectomy versus Bladder-Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Biasin Cancer Observational Comparative Effectiveness Research
Justin E. Bekelman(University of Pennsylvania Health System), Nandita Mitra(University of Pennsylvania), Elizabeth A. Handorf(Fox Chase Cancer Center), David J. Vaughn(University of Pennsylvania), John P. Christodouleas(Elekta (Sweden)), Craig Evan Pollack(Johns Hopkins University), Thomas Ten Have, Daniel Polsky(Johns Hopkins University), Thomas J. Guzzo(Hospital of the University of Pennsylvania), Matthew J. Resnick(Vanderbilt University Medical Center), Samuel Swisher‐McClure(University of Pennsylvania)
Cited by 71
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
|Journal of Clinical Oncology|2007|799
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688